参一胶囊联合卡培他滨治疗晚期乳腺癌临床观察  

Observation of Treating Advanced Breast Cancer with Ginsenoside Rg3 Combining with Capecitabine

作　　者：寇小格[1] 梁东良[2] 李小瑞[1] 

机构地区：[1]新乡医学院第一附属医院肿瘤科,河南卫辉453100 [2]新乡医学院第一附属医院急诊科,河南卫辉453100

出　　处：《肿瘤防治研究》2011年第3期319-321,共3页Cancer Research on Prevention and Treatment

摘　　要：目的评价参一胶囊联合卡培他滨治疗晚期乳腺癌的疗效、机制及对化疗不良反应和生活质量的影响。方法采用前瞻性随机对照研究,把56例晚期乳腺癌患者分为治疗组与对照组。治疗组28例,给予参一胶囊联合卡培他滨治疗;对照组28例单纯给予卡培他滨治疗。结果治疗组和对照组有效率分别为35.7%、25%。1年生存率分别为68%、50%,差异均无统计学意义。治疗组白细胞减少率和疲劳发生率分别为17.9%、7.1%,对照组分别为42.9%、32.1%,两组白细胞减少率、疲劳发生率比较差异均有统计学意义。治疗组与对照组相比能显著降低VEGF的值,提高了生活质量。结论参一胶囊联合卡培他滨治疗晚期乳腺癌有提高患者生存期的趋势,并可以减少化疗引起的疲劳、白细胞降低等不良反应,提高患者的生活质量等,其机制可能与参一胶囊有抗血管生成作用等有关。Objective To explore the effect of ginsenoside Rg3（Shenyi Capsule） combining with Capecitabine on antitumor efficacy,mechanism,toxicity and quality of life in patients with advanced breast cancer.Methods The prospective,randomized,controlled method was adopted.56 patients with advanced breast cancer were randomly assigned to trial group（28 cases）and contral group（28 cases）,the trial group was administered with ginsenoside Rg3 combining with Capecitabine and the contral group was administered with Capecitabine alone.Results The response rate in trial group and control group was 35.7% and 25%,respectively.The 1-year survival rate was 68% and 50%,respectively.There was no significant difference between the 2 groups（P0.05）.Results： In trial group,the major hematologic toxicities was neutropenia 17.9%,with a 7.1% fatigue,while the rates of neutropenia and fatigue were 42.9% and 32.1% in control group,respectively.There was significant difference between the two groups in this case.Compared with the control group,the vascular endothelial growth factor（VEGF） value was significantly reduced and the quality of life was significantly improved in the trial group.Conclusion Ginsenoside Rg3 combining with Capecitabine trended to prolong the survival time of patients with advanced breast cancer.Moreover,ginsenoside Rg3 could reduce the adverse effects of chemotherapy and improve the quality of life.The mechanism might be correlated with its antiangiogenic effect.

关 键 词：参一胶囊 乳腺癌 化疗不良反应 

分 类 号：R737.9[医药卫生—肿瘤] R730.58[医药卫生—临床医学]